ReviewBriefings in bioinformatics2026
Decoding disease and therapy through multiomics integration and systems analysis.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Advanced Pulmonary Drug Delivery Systems: A Narrative Review.Pulmonary therapy · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Computational multiomics methods are based on machine learning methods, and are primarily used for classifying patients into subtypes, discovering novel biomarkers, drug repurposing, and advancing precision medicine. Advances in high-throughput technologies have enabled comprehensive profiling of multiple molecular layers, resulting in the emergence of multiomics approaches for a more accurate understanding of disease mechanisms, therapeutic targets, and biological heterogeneity. This review examines current applications of multiomics in oncology, ageing, and immune-mediated diseases, highlighting the strengths and challenges of integrative models in understanding disease mechanisms, identifying biomarkers, and guiding precision therapies. Integration strategies, from early to late fusion and horizontal to vertical frameworks, are also examined alongside recent advances in computational platforms and preprocessing techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.